Immunology and Microbiology
Chimeric Antigen Receptor T-Cell
100%
Human Immunodeficiency Virus Infection
72%
Human Immunodeficiency Virus
71%
B Cell
55%
Severe Acute Respiratory Syndrome Coronavirus 2
50%
Monospecific Antibody
50%
CCR5
50%
Clustered Regularly Interspaced Short Palindromic Repeat
50%
Chimeric Antigen Receptor
50%
Antigen Specificity
50%
Cell Expansion
50%
Antibody-Dependent Cell-Mediated Cytotoxicity
50%
TLR9
50%
Natural Killer Cell
50%
Neutralizing Antibody
38%
Therapeutic Antibodies
25%
Vaccine Efficacy
16%
Epitope
16%
Chimeric Antigen Receptor T-Cell Therapy
14%
Cell Surface
12%
CRISPR/Cas9
11%
Cell Activation
11%
Single-Cell Sequencing
8%
Virus Evolution
8%
Virus Neutralization
8%
Monoclonal Antibody
8%
Cryo-Electron Microscopy
8%
Receptor Binding
8%
SARS Coronavirus
8%
Transcriptomics
8%
Cell Selection
8%
Target Cell
7%
Viral Disease
7%
Engraftment
7%
Viral Protein
7%
Engineered Cell
7%
Single-Chain Variable Fragment
5%
CD4
5%
Activation-Induced Cytidine Deaminase
5%
Mouse Model
5%
Adoptive Immunotherapy
5%
Humanized Mouse
5%
CD16
5%
Peripheral Blood Mononuclear Cell
5%
Interferon Type I
5%
Agonist
5%
Cell Killing
5%
Tumor Cell Line
5%
Medicine and Dentistry
B Cell
50%
Cell Function
50%
Cell Differentiation
50%
Toll Like Receptor 9
50%
Lymph Node
50%
Lefitolimod
50%
Chimeric Antigen Receptor T-Cell
50%
Human Immunodeficiency Virus Infection
50%
Cell Expansion
50%
Human Immunodeficiency Virus
26%
Chimeric Antigen Receptor T-Cell Immunotherapy
14%
Antiretroviral Therapy
12%
Plasmacytoid Dendritic Cell
11%
Infection
11%
Immunotherapy
11%
Engraftment
7%
Viral Protein
7%
Hematologic Malignancy
7%
Cell Surface
7%
Virus Infection
7%
Target Cell
7%
Engineered Cell
7%
Cancer
5%
Retroperitoneal Lymph Node Dissection
5%
Clinical Trial
5%
Malignant Neoplasm
5%
Glycosylation
5%
Somatic Hypermutation
5%
Activation Induced Cytidine Deaminase
5%
Natural Killer Cell
5%
Cell Activity
5%
Interferon
5%
T Cell
5%
Keyphrases
T Cell Persistence
50%
T Cell Expansion
50%
Antibody-dependent Cellular Cytotoxicity
50%
Direct Killing
50%
Chimeric Antigen Receptor T-cell Therapy
14%
Chronically Infected Cells
7%
Antigen Exposure
7%
Antigen Density
7%
Engineered Cells
7%
Viral Proteins
7%
Chronic Viral Infection
7%
Post-activation
7%
Activation Strategy
7%
Killing Assay
7%
Human Differences
7%
